Psychedelic retreats — multi-day stays where guests take ayahuasca, psilocybin mushrooms, or 5-MeO-DMT under loose supervision — are a fast-growing wellness segment with almost no regulation, even after several recent participant deaths [1]. The Associated Press reports that the industry has expanded into Oregon, Colorado, and the Netherlands, with prices ranging from $1,500 to over $10,000 a week [1].

The clinical knowledge gap is the story. Psychedelics under FDA-trial conditions are screened for cardiac risk, prior psychosis, and serotonergic drug interactions; retreat operators frequently are not [1]. The AP names cases of deaths and serious psychiatric injury where prior conditions were not flagged or where reactions to ibogaine and ayahuasca went unrecognized [1].

State legalization has run ahead of state oversight. Oregon's Measure 109 created a licensed psilocybin program in 2023, but most retreats sit outside it, in the same legal gray zone yoga therapists and wellness coaches occupy [1]. Practitioners told the AP they want a national professional standard. Federal regulators have not signaled one.

The pattern is the wellness equivalent of raw milk: a state-by-state legalization story moving faster than the safety data, with operators competing on aesthetic rather than clinical credentials. The deaths are no longer hypothetical, and the AP names them. Whether the federal regulators that already classify psilocybin and DMT as Schedule I act on the safety side, or whether decriminalization races further ahead of medical screening, is the next read on this thread.

-- NORA WHITFIELD, Chicago